Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody

Publisher： Karger

E-ISSN： 2296-5262|38|4|185-192

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.38, Iss.4, 2015-03, pp. : 185-192

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 701-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 5, 2015-05 ,pp. : 469-477

John Wiley & Sons Inc

Access to resources Recommend Favorite

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+BL and pre‐B‐ALL

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 763-775

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunoglobulin VH Genes and CD38 Expression Analysis in B-Cell Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 116, Iss. 1, 2006-07 ,pp. : 72-74

Karger

Access to resources Recommend Favorite

HCV‐associated B‐cell non‐Hodgkin lymphomas and new direct antiviral agents

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 1478-3223, Iss. 10, 2015-10 ,pp. : 2222-2227

John Wiley & Sons Inc

Access to resources Recommend Favorite